Author (et al.) , year | Country | Study design | Patients with T2DM (n) | Age (years)a | Sex ratio (M/F) | Duration of T2DM (years)a | Patients with sarcopenia (n) | Prevalence ofsarcopenia (%) | Diagnostic criterion | Definition of sarcopenia | Diagnostic modality |
---|---|---|---|---|---|---|---|---|---|---|---|
Ken 2021 | Japan | The MUSCLES-DM longitudinal study | 588 | 70.0 ± 8.9 | 346/242 | NA | 37 | 6.3 | LSMI | AWGS | BIA |
Kang 2021 | Korea | The Korean frailty and aging cohort study (KFACS) | 2403 | 76.0 ± 3.9 | 1134/1269 | NA | 353 | 14.7 | LMM + LMS | AWGS/FISH | DEXA |
Takahashi 2020 | Japan | KAMOGAWA-DM Cohort Study (prospective cohort study) | 351 | 66.6 ± 10.6 | 192/159 | 14.1 ± 10.0 | 58 (W: 22, M:46) | 16.5 | LMM + LMS | AWGS | BIA |
Sung 2020 | Korea | Observational longitudinal study | 309 | 62.7 ± 10.5 | 215/94 | NA | 75 | 24.3 | LSMI | EWGSOP | CT |
Seo 2020 | Korea | Cross-sectional study | 4210 | 57.4 ± 10.8 | 2160/2050 | 7.8 ± 7.3 | 1240 | 29.5 | LSMI | KNHANES | BIA |
Pechmann 2020 | Brazil | Cross-sectional study | 177 | 65.6 ± 8.6 | 63/114 | 15.4 ± 8.2 | 23 | 12.9 | LMM | FISH | DEXA |
Nakanishi 2020 | Japan | Cross-sectional study | 1137 | 73.7 ± 6.3 | 661/476 | 17.2 ± 10.3 | 142 (W: 85, M: 57) | 12.5 | LMM + LMS | AWGS | DEXA |
Mori 2020 | Japan | Multi-institutional joint cross-sectional study | 645 | 72.4 ± 7.9 | 390/255 | 16.6 ± 11.5 | 76 (W: 29, M: 47) | 11.8 | LSMI | AWGS | BIA |
Beretta 2020 | Brazil | Prospective cohort study | 306 | 71.35 ± 6.45 | NA | NA | 144 | 47.1 | LMM + LMS | EWGSOP | inextensible tape measure |
Sazlina 2020 | Malaysia | The MUSCLES-DM longitudinal study | 506 | 67.6 ± 6.8 | 202/304 | NA | 144 (W: 75, M: 69) | 28.5 | LMM | AWGS | BIA |
Jung 2020 | Korea | Cross-sectional study | 102 | 55. 9 ± 9.8 | 65/37 | 9 (2.4–5.3) | 12 (W: 4, M: 8) | 11.8 | LMM | AWGS | BIA |
Gorial 2020 | Iraq | Case–control study | 65 | 57.0 ± 7.7 | 23/42 | 7.2 ± 6.0 | 10 | 15.4 | LMM + LMS | EWGSOP | DEXA |
Mauren 2020 | Brazil | Cross-sectional study | 484 | 68.3 ± 5.6 | 224/260 | 14(8–22) | 58 (EWGSOP1:41EWGSOP2:17) | 12.0 | LMM + LMS | EWGSOP1/2 | BIA |
Cui 2020 | China | Cross-sectional study | 132 | 73.5 (68–77.25) | 59/73 | 14.0 (5.0–22.0) | 38 | 28.8 | LSMI + LMM | AWGS | DEXA |
Chen 2020 | China | Cross-sectional observational study | 1732 | NA | 654/1078 | NA | 148 (W: 117, M: 31) | 10.37 | LMM + LMS | AWGS | BIA |
Yanagita 2019 | Japan | Retrospective cohort study | 108 | 76.2 ± 67.3 | 47/61 | 14.3 ± 12.1 | 38 (W: 25, M: 13) | 35.2 | LMM + LMS | AWGS | BIA |
Okamura 2019 | Japan | KAMOGAWA-DM cohort study(prospective cohort study) | 433 | 65.4 ± 11.1 | 236/197 | 10.3 ± 10.1 | 32 (W: 16, M: 16) | 7.4 | LSMI | AWGS | DEXA |
Ken 2019 | Japan | the MUSCLES-DM longitudinal study | 746 | 69.9 ± 9.0 | 450/296 | 15.8 ± 11.6 | 52 (W: 20, M: 32) | 7.0 | LSMI | AWGS | BIA |
Kaji 2019 | Japan | The KAMOGAWA-DM cohort study | 144 | 71.4 ± 6.7 | 82/62 | 15.2 ± 9.4 | 17 (W: 5, M: 12) | 11.8 | LSMI | AWGS | BIA |
Noriko 2019 | Japan | Cross-sectional study | 138 | 75.0 ± 5.3 | 72/66 | 15.3 ± 10.8 | 17 | 12.3 | LMM + LMS | AWGS | DEXA |
Fung 2019 | Singapore | Cross-sectional study | 387 | 68.3 ± 5.7 | 206/181 | NA | 106 (W: 61, M: 45) | 27.4 | LMM + LMS | AWGS | BIA |
Trierweiler 2018 | Brazil | Cross-sectional study | 83 | 65.84 ± 8.82 | 24/59 | 15.55 ± 8.67 | 13 | 15.7 | LSMI | FISH | DEXA |
Murai 2018 | Japan | Cross-sectional study | 183 | 64.7 ± 12.6 | 126/57 | 9 (3–21) | 41 (W: 15, M: 26) | 22.0 | LMM | AWGS | BIA |
Hashimoto 2018 | Japan | A cross-sectional study of the KAMOGAWA-DM cohort study | 146 | 72.6 ± 5.9 | 86/60 | 15.3 ± 9.3 | 21 (W: 5, M: 16) | 14.4 | LSMI | AWGS | BIA |
Murata 2017 | Japan | Cross-sectional study | 288 | 73.3 ± 6.1 | 151/137 | 17.0 ± 10.0 | 44 (W: 21, M: 23) | 15.3 | LSMI | AWGS | BIA |
Bouchi 2017 | Japan | Cross-sectional study | 238 | 64 ± 12 | 145/93 | 8 (3–14) | 42 | 17.6 | LMM + LMS | AWGS | DEXA |
Wang 2016 | China | Cross-sectional study | 236 | 68.4 ± 7.9 | 116/120 | 9.31 ± 7.32 | 35 (W: 15, M: 20) | 14.8 | LSMI | AWGS | BIA |
Tanaka 2015 | Japan | Cross-sectional study | 191 | 60.2 ± 12.5 | 191/0 | 9.8 ± 8.7 | 85 (W: 0, M: 85) | 44.5 | LSMI | EWGSOP | DEXA |